Publication Name	World Journal of Clinical Cases
Manuscript ID	86340
Country	China

Received	2023-06-13 18:32
Peer-Review Started	2023-06-13 18:33
To Make the First Decision
Return for Revision	2023-08-08 03:51
Revised	2023-08-17 02:30
Second Decision	2023-08-23 02:48
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2023-08-23 07:56
Articles in Press	2023-08-23 07:56
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2023-08-31 09:34
Publish the Manuscript Online	2023-09-20 16:48

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Case Report
Article Title	Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Si-Cong Chen, Dong-Heng Ma and Jia-Jian Zhong
ORCID	Author(s) ORCID Number Si-Cong Chen http://orcid.org/0000-0003-0968-4536 Dong-Heng Ma http://orcid.org/0000-0002-4548-9343 Jia-Jian Zhong http://orcid.org/0000-0002-9018-3255
Funding Agency and Grant Number
Corresponding Author	Jia-Jian Zhong, MM, Surgeon, Hepatobiliary and Pancreatic Surgery, Huazhong University of Science and Technology Union Shenzhen Hospital, No. 89 Taoyuan Road, Nanshan District, Shenzhen 518052, Guangdong Province, China. jjzhong11@163.com
Key Words	Esophageal squamous cell carcinoma; Toripalimab; Anlotinib; Complete response; Case report
Core Tip	Toripalimab and anlotinib have emerged as second-line or above-line treatment options for advanced esophageal cancer. However, their objective remission rates and progression-free survival are low when used alone. We report a case of complete response after combination therapy of toripalimab and anlotinib in a patient newly diagnosed with advanced esophageal squamous cell carcinoma. The patient was in remission for 14 mo. Hence, toripalimab combined with anlotinib may be a new and effective treatment for advanced unresectable esophageal squamous cell cancer.
Publish Date	2023-09-20 16:48
Citation	Chen SC, Ma DH, Zhong JJ. Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report. World J Clin Cases 2023; 11(27): 6579-6586
URL	https://www.wjgnet.com/2307-8960/full/v11/i27/6579.htm
DOI	https://dx.doi.org/10.12998/wjcc.v11.i27.6579

Full Article (PDF)	WJCC-11-6579-with-cover.pdf
Full Article (Word)	WJCC-11-6579.docx
CARE Checklist–2016	86340-CARE Checklist (2016) .pdf
Manuscript File	86340_Auto_Edited-JLW.docx
Answering Reviewers	86340-Answering reviewers.pdf
Audio Core Tip	86340-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	86340-Conflict-of-interest statement.pdf
Copyright License Agreement	86340-Copyright license agreement.pdf
Signed Consent for Treatment Form(s) or Document(s)	86340-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	86340-Language certificate.pdf
Peer-review Report	86340-Peer-review(s).pdf
Scientific Misconduct Check	86340-Bing-Qu XL-2.png
Scientific Editor Work List	86340-Scientific editor work list.pdf